Endocrine System Diseases
Pathological processes of the ENDOCRINE GLANDS, and diseases resulting from abnormal level of available HORMONES.
Subtype terms (11)
More specific conditions that are subtypes of Endocrine System Diseases in the MeSH hierarchy.
- Adrenal Gland Diseases
14 drugs (8 approved, 6 experimental)
- Bone Diseases, Endocrine
4 drugs (3 approved, 1 experimental)
- Diabetes Mellitus
899 drugs (388 approved, 511 experimental)
- Dwarfism
6 drugs (5 approved, 1 experimental)
- Endocrine Gland Neoplasms
17 drugs (11 approved, 6 experimental)
- Gonadal Disorders
14 drugs (11 approved, 3 experimental)
- Parathyroid Diseases
20 drugs (17 approved, 3 experimental)
- Pituitary Diseases
18 drugs (14 approved, 4 experimental)
- Polyendocrinopathies, Autoimmune
1 drug approved
- Thyroid Diseases
47 drugs (36 approved, 11 experimental)
- Tuberculosis, Endocrine
Drugs by status
Approved for this indication (3)
Phase 4 trials (6)
Phase 3 trials (20)
Phase 2 trials (35)
- mifepristone
- anlotinib
- acetylcysteine
- urea
- irinotecan
- doxycycline
- fluorodopa
- gsk2256294
- levocarnitine
- niacin
- niraparib
- pentetreotide
- carboplatin
- sitagliptin
- bevacizumab
- finasteride
- testosterone
- digoxin
- capecitabine
- azithromycin
- insulin lispro
- gad-alum
- menopausal gonadotropin
- cisplatin
- liothyronine
- usistapide
- clomifene
- fludeoxyglucose f-18
- oncoxin-viusid
- gfb-887
- +5 more
Phase 1 trials (5)
Organizations
Organization Involved with Phase 4 Indications (50)
- Novo Nordisk
- Genentech
- Merck KGaA
- Pfizer
- Dong-A Pharmaceutical
- GeneScience Pharmaceuticals Co., Ltd.
- Huazhong University of Science and Technology
- Central South University
- Hebei University
- Anhui Medical University
- First People's Hospital of Hangzhou
- Guangxi Medical University
- Guangzhou Medical University
- Hacettepe University
- Harbin Medical University
- Kunming Medical University
- Nanjing Medical University
- Shandong Provincial Hospital
- Shaoxing Second Hospital
- University of Southern California
- Xuzhou Medical University
- Capital Medical University
- Fudan University
- Peking University
- Wenzhou Medical University
- Dalian Medical University
- Soochow University
- Xiamen University
- Zhejiang Chinese Medical University
- Zhengzhou University
- +20 more
Organization Involved with Phase 3 Indications (24)
- Celgene
- Merck Serono
- Eli Lilly
- AEterna Zentaris
- BioPartners GmbH
- Cinnagen
- GlaxoSmithKline
- LG
- Teva
- Versartis Inc.
- Xiamen Amoytop Biotech Co., Ltd.
- Daewoong Pharmaceutical Co. LTD.
- National Heart, Lung, and Blood Institute (NHLBI)
- Baylor University
- Keio University
- Jilin University
- Tel Aviv University
- University of Colorado, Denver
- Ascendis Pharma, Inc.
- Opko
- University of Colorado
- National Center for Child Health and Development, Japan
- Ferring
- Visen Pharmaceuticals
Organization Involved with Phase 2 Indications (37)
- Ambrx
- AstraZeneca
- Catalysis SL
- Diamyd
- Diurnal Limited
- Altus Pharmaceuticals
- Genexine, Inc.
- TesoRx Pharma, LLC
- Stem Cells Arabia
- North Florida Foundation for Research and Education
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Aarhus University
- Ain Shams University
- Institut National de la Santé Et de la Recherche Médicale, France
- Johns Hopkins University
- Royan Institute
- University of Florida
- University of Oslo
- Vinmec International Hospital
- University of Naples Frederico II
- Uppsala University
- Vanderbilt University
- Hanmi Pharmaceutical
- Zhongsh Ophthalmic Center
- University of Lyon
- University of Oxford
- Premier Research Group
- University of Gothenburg
- Accelsiors
- +7 more
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (6)